Skip to main content

Recurrent or Progressive IDH1 Mutated Glioma NEO100-01

Status: Open to Enrollment
Email Us To Enroll

Study Details

View study details on clinicaltrials.gov.

Locations

  • San Francisco
  • Roseville
  • Palo Alto

Clinical Trial FAQs

Information for patients and study volunteers, including frequently asked questions.

An Open-Label, Phase 1/2A Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent or Progressive Grade III or Grade IV Gliomas With IDH1 Mutation

Akanksha Sharma, M.D.
Akanksha Sharma, M.D.
Principal investigator
View Profile

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?